PRME

Prime Medicine Inc

3.94

Oct 20 • 1:05 PM ET +0.11 (2.87%)

Healthcare Biotechnology USA Small NASD

Peers: BEAM NTLA EDIT CRSP WVE DTIL KRRO SANA QURE RGNX

| Held by: ARKG XBI VTI IWM VXF IWO IBB SCHA VTWO IWC

Index	RUT
Market Cap	714.60M
Enterprise Value	732.01M
Income	-187.89M
Sales	4.07M
Book/sh	0.22
Cash/sh	0.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	146
IPO	Oct 20, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	175.58
P/B	17.89
P/C	7.52
P/FCF	-
EV/EBITDA	-
EV/Sales	179.86
Quick Ratio	3.05
Current Ratio	3.05
Debt/Eq	2.83
LT Debt/Eq	2.60
Option/Short	Yes / Yes

EPS (ttm)	-1.09
EPS next Y	-0.92
EPS next Q	-0.24
EPS this Y	28.53%
EPS next Y	4.16%
EPS next 5Y	13.58%
EPS past 3/5Y	2.55% -91.28%
Sales past 3/5Y	- -2.32%
EPS Y/Y TTM	32.10%
Sales Y/Y TTM	-17.90%
EPS Q/Q	41.64%
Sales Q/Q	3.50%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	6.69% -48.74%

Insider Own	46.28%
Insider Trans	0.00%
Inst Own	49.33%
Inst Trans	6.52%
ROA	-71.16%
ROE	-373.29%
ROIC	-131.10%
Gross Margin	-81.64%
Oper. Margin	-4824.94%
Profit Margin	-4613.11%
SMA20	17.29%
SMA50	17.16%
SMA200	13.19%
Trades

Shs Outstand	180.74M
Shs Float	97.44M
Short Float	32.96%
Short Ratio	9.23
Short Interest	32.12M
52W High	6.30 -37.46%
52W Low	2.67 47.56%
Volatility	10.41% 10.63%
ATR (14)	0.34
RSI (14)	58.87
Beta	2.33
Rel Volume	0.93
Avg Volume	3.48M
Volume	1,867,033

Perf Week	18.67%
Perf Month	23.51%
Perf Quarter	27.50%
Perf Half Y	3.41%
Perf YTD	13.54%
Perf Year	-36.25%
Perf 3Y	-44.82%
Perf 5Y	-
Perf 10Y	-
Recom	1.46
Target Price	7.33
Prev Close	3.83
Price	3.94
Change %	2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-26	Resumed	Chardan Capital Markets	Buy	$7
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$9
Jun-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$8
Mar-12-26	Initiated	Oppenheimer	Outperform	$11
May-27-25	Downgrade	Citigroup	Buy → Neutral	$1.50
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27

Show Previous Ratings

Oct-05-26 08:00AM	Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease (GlobeNewswire) +7.72%
Sep-24-26 04:47PM	Prime Medicine stock surges on FDA IND clearance (Investing.com) -5.54%
04:01PM	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
08:46AM	Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
Sep-23-26 05:49PM	CRSP, NTLA, BEAM, PRME, EDIT Shares Slip Did Claude Just Spook Gene-Editing Stocks? (Stocktwits) -11.58%
08:00AM	Loading…
Aug-06-26 08:00AM	Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com)
Jul-23-26 04:05PM	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease (GlobeNewswire)
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com) -10.64%
Jul-08-26 04:10PM	Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle (Investor's Business Daily) +15.79% -8.44%
12:47PM	PRME Surges 15% After Winning Arbitration Against Beam Clears Path To Human Trials For Its Gene-Editing Drug (Stocktwits)
08:00AM	Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics (GlobeNewswire)
05:07AM	Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal (BioPharma Dive)
Jun-22-26 08:00AM	Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Jun-18-26 08:00AM	Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease (GlobeNewswire)
08:00AM	Loading…
Jun-03-26 08:00AM	Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-28-26 08:00AM	Prime Medicine to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-07-26 08:00AM	Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.65%
Apr-16-26 08:00AM	Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer (GlobeNewswire)
Mar-31-26 08:49PM	The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step (PR Newswire) +10.48%
Mar-24-26 10:00AM	Advanced Cell-based Therapy Booming the Success for Healthcare Sector (PR Newswire)
Mar-08-26 12:57PM	Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway (Insider Monkey)
Mar-03-26 09:15AM	Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -9.23%
08:00AM	Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-25-26 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.83%
Feb-11-26 05:15PM	Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Jan-07-26 08:00AM	Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +9.19%
Jan-02-26 01:29PM	Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize (PR Newswire)
Dec-31-25 11:12AM	LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases (Insider Monkey)
Dec-30-25 11:45PM	Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data (Insider Monkey)
08:05AM	Loading…
Dec-07-25 08:05AM	Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease (GlobeNewswire)
Nov-25-25 08:00AM	Prime Medicine to Present at 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-11-25 08:00AM	Prime Medicine to Present at Jefferies Global Healthcare Conference (GlobeNewswire) +11.21%
Nov-07-25 10:21AM	CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.85%
08:10AM	Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 08:01AM	Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (GlobeNewswire) -7.69%
Oct-30-25 04:01PM	Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy (GlobeNewswire) +13.56%
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV) +9.88%
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 04:50PM	Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?) (Barchart) +16.46%
Aug-26-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 09:10AM	Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -9.58%
08:00AM	Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-25 04:01PM	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.02% +11.39%
Jul-31-25 11:40PM	JonesTrading Maintains a Buy on Prime Medicine (PRME) (Insider Monkey)
Jul-30-25 09:33PM	Prime Medicine Announces Pricing of Public Offering (GlobeNewswire)
04:01PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:55AM	Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-20-25 12:35AM	BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT (Insider Monkey)
Jul-16-25 08:10AM	Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy (Business Wire) -5.83%
07:00AM	Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis (GlobeNewswire)
Jul-07-25 12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com) +22.19%
Jul-06-25 04:01AM	Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data (Insider Monkey)
May-29-25 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-25 02:24PM	Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty (Insider Monkey)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks) +5.58%
May-19-25 08:31AM	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition (GlobeNewswire) -16.04%
08:30AM	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease (GlobeNewswire)
08:28AM	Prime Medicine claims proof of concept, but lays off staff in pivot (BioPharma Dive)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.04%
08:00AM	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-07-25 05:10PM	Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.77%
May-05-25 08:25AM	Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.55%
Apr-25-25 10:51AM	Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 (Seeking Alpha)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -10.30%
Mar-20-25 06:48PM	Why Prime Medicine Stock Was Climbing Higher This Week (Motley Fool)
Mar-19-25 02:56PM	Why Prime Medicine Stock Is Soaring Today (Fool) +13.64%
Mar-18-25 08:09AM	Prime sets sights on liver, lung disease as next target for its gene editing tech (BioPharma Dive)
07:00AM	Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)

Show Previous News

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

M.P.A.Mr. Jeffrey D. Marrazzo M.B.A.

CEO & DirectorDr. Allan Reine M.D.

Chief Technical OfficerDr. Ann L. Lee Ph.D.

Ph.D.Dr. Andrew Anzalone M.D.

Co-Founder & Member of Scientific Advisory BoardDr. David R. Liu Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRME

Prime Medicine Inc

Upgrade your Finviz experience